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Abstract
Background: It is unknown, on the proteomic level, whether the protein patterns of tumors change during metastasis or
whether markers are present that allow metastases to be allocated to a specific tumor entity. The latter is of clinical interest
if the primary tumor is not known.
Methodology/Principal Findings: In this study, tissue from colon-derived liver metastases (n=17) were classified, laser-
microdissected, and analysed by ProteinChip arrays (SELDI). The resulting spectra were compared with data for primary
colorectal (CRC) and hepatocellular carcinomas (HCC) from our former studies. Of 49 signals differentially expressed in
primary HCC, primary CRC, and liver metastases, two were identified by immunodepletion as S100A6 and S100A11. Both
proteins were precisely localized immunohistochemically in cells. S100A6 and S100A11 can discriminate significantly
between the two primary tumor entities, CRC and HCC, whereas S100A6 allows the discrimination of metastases and HCC.
Conclusions: Both identified proteins can be used to discriminate different tumor entities. Specific markers or proteomic
patterns for the metastases of different primary cancers will allow us to determine the biological characteristics of
metastasis in general. It is unknown how the protein patterns of tumors change during metastasis or whether markers are
present that allow metastases to be allocated to a specific tumor entity. The latter is of clinical interest if the primary tumor
is not known.
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Introduction
Distant metastases are the principal causes of death in patients
with colorectal carcinoma (CRC). A common site of metastases
derived from CRC is the liver.[1] The underlying mechanisms of
liver metastasis of CRC are not fully understood, but metastases
are at least involved in tumor initiation and promotion,
uncontrolled proliferation, angiogenesis, invasion, intra- and
extravasation, and colony formation at the liver site.[2,3] The
analysis of the expression of a single protein is not practical
because these processes seem to be induced by the altered
expression of several different proteins. Proteomic approaches are
practical in the global analysis of altered protein patterns, in which
diverse mass spectrometry (MS)-based methods are used for these
kinds of high-throughput analyses.[4,5] In this context, surface-
enhanced laser desorption/ionization (SELDI) is a proteomic
high-throughput technique that uses chromatographic surfaces
that are able to retain proteins depending on their physico-
chemical properties, followed by direct analysis via time-of-flight
mass spectrometry (TOF-MS).[6] A multitude of studies using
ProteinChip technology have been carried out to establish the
protein profiles of biological fluids, especially serum samples.[7–9]
Because this technique demands only a small amount of sample, it
can be used for small biopsies or microdissected tissues, which
produce the homogeneous tissue samples typically used in cancer
research. The separation of functional tissue areas can be achieved
by laser-based microdissection (for review see [10]). When laser
microdissection was first introduced as a novel preparation
technique in 1998, the challenge was to prove that reliable results
could be achieved by selecting defined small amounts of isolated
cells from complex tissue sections.[11] Since then numerous
applications has been published in different fields and has proven
its necessity.[12] Microdissected tissue material free from contam-
inating and unwanted tissue components is extremely important
for the production of clean data for biomarker identification in
cancer diagnostics and in determining the clonal heterogeneity of
tumors. We have shown in a previous study that the detection of
differentially expressed proteins was only possible in pure
microdissected samples.[13] Laser-based microdissection has
previously been combined with ProteinChip technology to identify
protein markers in several cancer types.[14–16]
The aim of this study was to analyse the protein patterns of liver
metastases derived from CRC (MTS) and detect biologically and
diagnostically relevant signals. We wanted to analyze whether it is
possible to draw conclusions from the proteome of the MTS on the
origin/localization of the primary tumor.
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Laser microdissection of tissue sections
All 17 human samples from liver metastases derived from CRC
(MTS) were obtained after surgical resection at the Department of
General and Visceral Surgery of the Friedrich Schiller University,
Jena. They were collected fresh, snap frozen in liquid nitrogen,
and stored at 280uC. Primary tumor specimens were categorized
according to the WHO classification. Most of these tumors were
classified as pT2 and pT3.
Laser microdissection was performed with a laser microdissec-
tion and pressure catapulting microscope (LMPC; Palm, Bernried,
Germany) as previously described.[17] Briefly, we microdissected
native air-dried cryostat tissue sections of approximately 3000–
5000 cells, each in a maximum of 20–30 min. Proteins were
extracted in 10 mL lysis buffer (100 mM Na-phosphate [pH 7.5],
5 mM EDTA, 2 mM MgCl2, 3 mM 2-b-mercaptoethanol, 0.1%
CHAPS, 500 mM leupeptin, and 0.1 mM PMSF) for 30 min on
ice. After centrifugation (15 min; 15,000 rpm) the supernatant was
immediately analysed or frozen in liquid nitrogen for a maximum
of one day.
Profiling microdissected liver-localized metastases
The protein lysates from microdissected metastatic tissues were
analysed on strong anion exchange arrays (Q10) (Bio-Rad), as
previously described.[17] In brief, Q10 array spots were pre-
incubated in a washing/loading buffer containing 100 mM Tris
buffer (pH 8.5) and 0.02% Triton X-100. Then 2 mL sample
Figure 1. Distribution of the intensities of peaks expressed significantly differently in liver metastases derived from colorectal
carcinoma (MTS), colorectal carcinoma tumor (CRC), and hepatocellular carcinoma (HCC) tumor margins. Upper panel: Distribution of
the intensities of the 10.175 kDa signal. Bottom panel: Distribution of the intensities of the 11.997 kDa signal. The spectra were obtained using Q10
arrays. X-axis indicates the sample groups, Y-axis the intensity (mA).
doi:10.1371/journal.pone.0003767.g001
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incubated at room temperature for 90 min in a humidified
chamber. After the samples had been washed three times with the
fresh buffer and twice with water, 260.5 mL of sinapinic acid
(saturated solution in 0.5% TFA/50% acetonitrile) were applied.
Mass analysis was performed with a ProteinChip Reader (Series
4000; Ciphergen Biosystems Inc., Fremont, CA), according to an
automated data collection protocol.
Immunodepletion assay
Two microlitres of anti-S100A6 antibody (ab 141; Swant,
Bellinzona, CH) or a specific antibody directed against S100A11
(rabbit polyclonal; Protein Tech Group, IL) were incubated with
10 mL of protein A–agarose (Sigma, St Louis, MO) for 15 min on
ice. A pellet was generated by centrifugation and the supernatant
was discarded. The pellet was washed twice with buffer containing
20 mM Hepes (pH 7.8), 25 mM KCl, 5 mM MgCl2, 0.1 mM
EDTA, and 0.05% NP-40. Then, lysate (5 mL) from the
microdissected tissue was incubated with this pellet for 45 min
on ice. As a negative control, 5 mL of the lysate was incubated for
45 min on ice with protein A–agarose without the specific
antibody. After incubation, the samples were cleared by
centrifugation and 3 mL of each supernatant (immunodepleted
sample) was analysed on the ProteinChip Arrays (Q10, BioRad).
Immunohistochemistry
Cryostat sections (8 mm) of MTS-containing tissue (n=5) or
CRC tissue (n=5) were placed on slides, air-dried for about 60 min
at 20uC, and fixed in paraformaldehyde, as described previous-
ly.[18] After fixation, the slides were treated in a microwave at 80
watts (363 min) in 10 mM citric acid (pH 6.0) to inhibit
endogenous peroxidase activity. They were then rinsed twice with
Tris-buffered saline (TBS; pH 7.4), and incubated overnight at 4uC
in a humidified chamber with the corresponding primary anti-
S100A6 antibody or anti-S100A11 antibody. The slides were rinsed
three times, for 10 min each, in TBS. The Vectastain Elite ABC kit
(Vector Laboratories, Burlingame, CA) and the Jenchrom pxbl-kit
(MoBiTec, Go ¨ttingen, Germany) were used according to the
manufacturers’ instructions to visualize the antibodies. Negative
controls were incubated with only the labelled secondary antibody.
Sections cut in parallel to the immunohistochemically treated
sections were stained with haematoxylin–eosin for better identifi-
cation of the different tissue areas. Immunohistochemical staining
was evaluated by a pathologist.
Figure 2. Immunodepletion assays of S100A6 and S100A11. Normalized ProteinChipH array profiles of metastatic tissue show that the peaks
representing S100A6 (A, 10.162 kDa) or S100A11 (B, 12.009 kDa) were detectable in the negative controls but only with decreased intensity with the
corresponding depleted probes. Reference peaks that were not influenced by immunodepletion are labelled with asterisks.
doi:10.1371/journal.pone.0003767.g002
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Mass spectra from ProteinChip arrays were normalized to a total
ion current and cluster analysis of the detected signals was
performed. The respective P values for MTS, CRC,[19] and
HCC [17] were determined with the CiphergenExpress program
(version 3.0; Ciphergen Biosystems Inc.). To calculate the P values,
normalized spectra with signals in the range of 2.5–200 kDa, with a
signal-to-noise ratio (S/N) of at least 10, were selected and analysed
with the Mann–Whitney U test for non-parametric data sets, and
the Kruskal–Wallis test. Receiver operating characteristic (ROC)
curves [20] were constructed for S100A6 and S100A11 expression
data derived CRC, MTS or HCC, respectively by plotting
sensitivity versus 1-specificity (CiphergenExpress 3.0).
Results
Proteomic analysis of microdissected tissues from liver
metastases derived from CRC, primary CRC, and HCC by
SELDI–MS
For this study, microdissected tissue probes containing about
3000–5000 cells each were successfully dissected from 17 liver
metastases derived from colorectal cancer (MTS) by an experienced
pathologist. All protein lysates were applied to strong anion
exchanger Q10 ProteinChip Arrays and analysed individually by
SELDI–MS on a ProteinChip Reader Series 4000 instrument. The
spectra generated from the MTS were compared with specific
spectra derived from primary CRC (n=14) and HCC (n=46),
which were generated as described previously [17,19], to detect any
distinguishing protein signals. In the range of 2.5–200 kDa, up to
372 peaks were detected with normalized intensities. After
evaluation with the CiphergenExpress program, many significantly
different signals (n=49) were detected for MTS, CRC, and HCC
(Table S1). Among these, the peak masses with markedly low P
values were selected for further identification and characterization.
The signals at 10.175 kDa (P=3.00610
29) and 11.997 kDa
(P=1.82610
26) were significantly upregulated in both MTS and
CRC compared with samples derived from HCC (Figure 1). The
signal with a molecular mass of 10.175 kDa was the most significant
single signal capable of discriminating between the two sample
groups in this analysis. The 11.997 kDa signal was ranked in 12th
position(TableS1).Representative examplesofSELDI–MS spectra
of MTS, CRC, and HCC are shown in Figure S1.
Identification of differentially expressed protein peaks
The interesting proteins with molecular masses of 10.175 kDa
and 11.997 kDa, which corresponded very well to the Ca
2+-
binding proteins S100A6 (NCBI NP_055439) and S100A11
(NCBI NP_005611), respectively, were also detected by Pro-
teinChip technology, as has been described by ours and other
groups [17,19,21]. To confirm that S100A6 and S100A11 match
the differentially expressed peaks observed at 10.175 kDa and
11.997 kDa, respectively, in this protein profiling analysis,
immunodepletion assays were carried out using microdissected
MTS tissue as the starting material. Analysis of the supernatants of
the immunodepletion assays by Q10 arrays showed that the peaks
corresponding to S100A6 and S100A11 were significantly
reduced. In the negative controls without specific antibodies, the
peaks were clearly detectable (Figure 2). The identification of other
differentially expressed proteins is in progress.
Characterization of the differentially expressed protein
signals
To assess the impact of S100A6 and S100A11 as discriminatory
signals for different tumorous tissue samples, we compared the
spectra derived from different sample groups in individual assays.
We found that S100A6 was significantly upregulated in CRC and
MTS compared with HCC (P=2.81610
26) (Figure 3). Hence,
S100A again ranked first as the most significant signal (Table S2).
An analysis of CRC and HCC showed that S100A6
(P=2.62610
27) and S100A11 (P=5.54610
27) were both signif-
icantly upregulated in the samples derived from CRC (Figure 4).
In this analysis, S100A6 and S100A11 ranked in third place and
fourth place, respectively, in the most significant signals (Table S3).
Interestingly, neither S100A6 nor S100A11 were significantly
differentially expressed in MTS compared with CRC (Table S4).
Localization of S100A6 and S100A11 in tissue
To confirm their identification and in particular to localize
S100A6 and S100A11 in tissue sections, we assessed their
Figure 3. ROC curve of S100A6 in liver metastases derived from colorectal carcinoma (MTS) and in hepatocellular carcinoma (HCC).
S100A6 is significantly upregulated in MTS.
doi:10.1371/journal.pone.0003767.g003
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istry using specific antibodies. All these tissues showed a positive
reaction to the antibodies directed against S100A6 or S100A11
(Figure 5). In contrast to these findings, only very poor signals were
detectable in the tissue surrounding the MTS (Figure 5A and D).
Interestingly, the immunoreactivity of the tumor cell complexes
was stronger at the tumor margin than that in the central tumor
area in CRC, when we used the specific antibody directed against
S100A6 (Figure 5E). Consistent with the SELDI analysis of HCC,
neither signal was detectable by immunohistochemistry (data not
shown).
Discussion
Liver metastasis of CRC is a major reason for the poor
prognosis of patients. An improved understanding of the
molecular and cellular mechanisms underlying metastasis would
contribute greatly to its early detection and treatment. The
initiation of MTS affects the expression of multiple proteins.[22–
24] The identification of proteins that are characteristic of
metastasis might allow the discrimination of different tumor
entities. To address this challenge, specific proteomic approaches
have been used that focus on the complex analysis of protein levels
in metastases using cell lines.[2527] Such altered expression
patterns have been detected for cytokeratin 18, tissue transgluta-
minase, Rho GDP-dissociation inhibitor 1, fibroblast-type tropo-
myosin, interleukin-18, annexin I, disulfide isomerase, heat shock
protein 60, peroxiredoxin 1, chlorine intracellular channel protein
1, and creatine kinase B chain, as well as for some ribosomal
proteins. Since the early 1990s, a number of studies have
investigated, with genomic approaches, tissues derived directly
from both primary tumors and organs involved in metastasis.[28–
31] This is, to the best of our knowledge, the first study to use a
proteomic approach in a comparative investigation of tissues
derived from different metastasising primary tumors and in the
identification of proteins that can discriminate between these
Figure 4. ROC curves of S100A6 and S100A11 in colorectal carcinoma (CRC) and in hepatocellular carcinoma (HCC). Both proteins are
significantly upregulated in CRC.
doi:10.1371/journal.pone.0003767.g004
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majority of SELDI–MS-based studies, we identified significantly
differentially expressed proteins. The Ca
2+-binding proteins
identified here, S100A6 and S100A11, can distinguish very clearly
between MTS, primary CRC, and primary HCC, as well as
between CRC and HCC. A number of additional signals were
detected that discriminate between MTS and CRC, but S100A6
and S100A11 do not. The identification of specific signals that can
distinguish between metastases and the primary tumor is in
progress. Until now, only two small studies have comparatively
assessed the expression of S100A6 in human colorectal mucosa,
primary colorectal adenocarcinomas, and liver metastases using a
specific western blot analysis [32,33]. In contrast, we analysed an
extended number of samples using a hypothesis-free proteomic
approach and thereby detected and identified S100A6 as a factor
with the potential to discriminate between primary HCC and
MTS. S100A6 and S100A11 belong to the group of S100 proteins
involved in the Ca
2+ signalling network, and regulate intracellular
activities such as cell growth and motility, cell-cycle progression,
transcription, and cell differentiation.[34,35] Both S100A6 and
Figure 5. Immunohistochemical analysis of S100A6 and S100A11 and corresponding H&E sections. (A) and (B) H&E section from liver
metastases derived from colorectal carcinoma (MTS) and colorectal carcinoma (CRC). (C) Corresponding section to (A) immunostained for S100A6
using a specific antibody. A positive immunohistochemical reaction was detectable in the MTS (labeled with arrows) and in adjacent necrotic tissue
(nec). The surrounding liver tissue was negative. (D) Corresponding section to (B). Scattered immunoreactive tumor cell complexes (labeled with
arrows) at the tumor periphery of a colorectal carcinoma (CRC) detected with anti-S100A6 antibody. (E) and (F) H&E section from liver metastases
derived from colorectal carcinoma (MTS) and colorectal carcinoma (CRC). (G) Corresponding section to (E). S100A11-positive tumor cell complex
(labeled with an arrow) in MTS. (H) Corresponding section to (F). Strong S100A11 immunoreactivity in CRC tumor cell complexes (labeled with
arrows). Immunoreactivity against S100A11 was stronger in the tumor margin compared to central tumor area.
doi:10.1371/journal.pone.0003767.g005
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linked to metastasis.[19,32,36,37]
In this study, we have demonstrated the potential of SELDI–
MS in characterizing metastasis in terms of protein profiles and in
discriminating between different tumor entities. In future, it would
be very interesting to assess and compare the protein profiles of
metastases derived from different types of metastasising tumors.
We might expect to find a panel of protein signals or a ‘‘metastatic
protein profile’’ that is common to all metastatic tissues. This panel
will presumably contain proteins involved in the coordination of
metastatic processes. Although neither S100A6 nor S100A11 can
discriminate between MTS and the corresponding primary CRC,
they can discriminate between primary CRC and primary HCC.
Perhaps more importantly, S100A6 is a potential candidate to
discriminate between MTS and primary HCC. The discrimina-
tion of primary HCC and its metastases located in the liver is
presently complicated and afflicted with difficulties.[38] Therefore,
S100A6 might provide some resolution of this problem.
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